Menu
Recruiting NCT05746650

Improving Tissue Repair After Injury in the Muscle-tendon Interface Muscle Tissue Injury

No phase Interventional Muscle Injury

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Electrical stimulation, Growth hormone (somatropin), Control (No electrical stimulation, nor growth hormone).
Who it may be relevant to
Registry conditions: Muscle Injury. Basic parameters: 18 years — 35 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Regulation of Protein Turnover in Connective Tissue From Muscle and Tendon Following Muscle Tissue Injury

Overview

The study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of GH or placebo following or without neuromuscular electrical stimulation of hamstring muscles.The overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.

Interventions

  • Procedure Electrical stimulation
    Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
  • Drug Growth hormone (somatropin)
    Daily injection of growth hormone
  • Other Control (No electrical stimulation, nor growth hormone)
    No electrical stimulation, nor growth hormone

Primary outcome measures

  • Difference in muscle and myotendinous junction protein synthesis in regenerating vs. control muscle [Time frame: 2 years]
Secondary outcome measures (8)
  • Difference in muscle protein synthesis in regenerating muscle, myotendinous junction tissue with or without growth hormone [Time frame: 2 years]
  • Single protein synthesis in regenerating vs. control muscle and myotendinous junction tissue [Time frame: 2 years]
  • Single protein synthesis in regenerating muscle and myotendinous junction tissue with or without growth hormone [Time frame: 2 years]
  • Tendon tissue synthesis from injured muscle vs. control muscle [Time frame: 2 years]
  • Difference in muscle protein synthesis in regenerating muscle, myotendinous junction, and tendon tissue with or without growth hormone [Time frame: 2 years]
  • Difference in muscle protein synthesis in regenerating vs. control muscle, myotendinous junction, and tendon tissue [Time frame: 2 years]
  • Number of satellite cells, fibroblasts and immune cells in renereting vs. control tissue, with and without growth hormone [Time frame: 2 years]
  • Mechanical properties of tissue with and without growth hormone [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Healthy men and women scheduled to undergo reconstructive knee surgery
  • BMI 18-35

Exclusion criteria

  • Former or current use of growth hormone or anabolic steroids
  • Use of corticosteroids in the past 3 months
  • Use of any medication known to affect muscle or tendon turnover
  • Former participation in a study using deuterated water
  • Chronic diseases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Basic science

Study locations

Denmark · 1 center
  • Bispebjerg Hospital — Copenhagen

Identifiers

NCT: NCT05746650 · BBH158

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗